Importance The morbidity and mortality associated with COVID-19 remain high despite
advances in standard of care therapy, and the role of anti-inflammatory agents that inhibit …

Background: The Coronavirus disease (COVID-19) pandemic is causing millions of
infections and hundreds of thousands of deaths worldwide. Cumulative clinical and …

OBJECTIVE: Janus Kinase (JAK) inhibitors have been extensively evaluated for their
potential in the management of various diseases. Despite previous research on this topic …

The development of therapies for SARS-CoV-2 infection, based on virus biology and
pathology, and of large-and small-scale randomized controlled trials, have brought forward …

The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant–Lilly) has been granted an FDA
Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in …

Abstract Objectives The Janus kinase (JAK) inhibitor baricitinib may block viral entry into
pneumocytes and prevent cytokine storm in patients with SARS-CoV-2 pneumonia. We …

We analyzed reports on safety and efficacy of JAK-inhibitors in patients with coronavirus
infectious disease-2019 (COVID-19) published between January 1st and March 6th 2021 …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Severe coronavirus disease 2019 (COVID-19) is characterised by pneumonia with
excessive systemic inflammation, referred to as a “cytokine storm”[1–3]. Dexamethasone …